EyePoint CEO says DME biology backs DURAVYU after wet AMD misses, at Jefferies London
EyePoint chief executive Dr. Jay Duker MD told the Jefferies Global Healthcare Conference in London that Phase 2 VERONA data and repeat-dosing safety support taking DURAVYU forward in DME alone after both wet AMD Phase 3 trials missed.
